These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 31869751)

  • 21. Comparative analysis of the phase III clinical trials of anti-PD1 monotherapy in head and neck squamous cell carcinoma patients (CheckMate 141 and KEYNOTE 040).
    Pai SI; Faivre S; Licitra L; Machiels JP; Vermorken JB; Bruzzi P; Gruenwald V; Giglio RE; Leemans CR; Seiwert TY; Soulieres D
    J Immunother Cancer; 2019 Apr; 7(1):96. PubMed ID: 30944020
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Immunotherapy for squamous cell carcinoma of the head and neck.
    Yokota T; Homma A; Kiyota N; Tahara M; Hanai N; Asakage T; Matsuura K; Ogawa T; Saito Y; Sano D; Kodaira T; Motegi A; Yasuda K; Takahashi S; Tanaka K; Onoe T; Okano S; Imamura Y; Ariizumi Y; Hayashi R;
    Jpn J Clin Oncol; 2020 Sep; 50(10):1089-1096. PubMed ID: 32776100
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evolving Role of Immunotherapy in Recurrent Metastatic Head and Neck Cancer.
    Le X; Ferrarotto R; Wise-Draper T; Gillison M
    J Natl Compr Canc Netw; 2020 Jul; 18(7):899-906. PubMed ID: 32634775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial.
    Ferris RL; Spanos WC; Leidner R; Gonçalves A; Martens UM; Kyi C; Sharfman W; Chung CH; Devriese LA; Gauthier H; Chiosea SI; Vujanovic L; Taube JM; Stein JE; Li J; Li B; Chen T; Barrows A; Topalian SL
    J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34083421
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of human papillomavirus type 16 E7-specific T cells against virally infected squamous cell carcinoma of the head and neck.
    Albers A; Abe K; Hunt J; Wang J; Lopez-Albaitero A; Schaefer C; Gooding W; Whiteside TL; Ferrone S; DeLeo A; Ferris RL
    Cancer Res; 2005 Dec; 65(23):11146-55. PubMed ID: 16322265
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Toxicities of systemic agents in squamous cell carcinoma of the head and neck (SCCHN); A new perspective in the era of immunotherapy.
    Saba NF; Mody MD; Tan ES; Gill HS; Rinaldo A; Takes RP; Strojan P; Hartl DM; Vermorken JB; Haigentz M; Ferlito A
    Crit Rev Oncol Hematol; 2017 Jul; 115():50-58. PubMed ID: 28602169
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence-Based Treatment Options in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck.
    Argiris A; Harrington KJ; Tahara M; Schulten J; Chomette P; Ferreira Castro A; Licitra L
    Front Oncol; 2017; 7():72. PubMed ID: 28536670
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of HPV-Related Squamous Cell Carcinoma of the Head and Neck: Pitfalls and Caveat.
    Perri F; Longo F; Caponigro F; Sandomenico F; Guida A; Della Vittoria Scarpati G; Ottaiano A; Muto P; Ionna F
    Cancers (Basel); 2020 Apr; 12(4):. PubMed ID: 32326465
    [No Abstract]   [Full Text] [Related]  

  • 29. Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial.
    Sato Y; Fukuda N; Wang X; Urasaki T; Ohmoto A; Nakano K; Yunokawa M; Ono M; Sato Y; Mitani H; Tomomatsu J; Takahashi S
    Cancer Manag Res; 2020; 12():4161-4168. PubMed ID: 32581587
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immunotherapy in Head and Neck Cancer: Where Do We Stand?
    Vallianou NG; Evangelopoulos A; Kounatidis D; Panagopoulos F; Geladari E; Karampela I; Stratigou T; Dalamaga M
    Curr Oncol Rep; 2023 Aug; 25(8):897-912. PubMed ID: 37213060
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nivolumab vs investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expression.
    Ferris RL; Blumenschein G; Fayette J; Guigay J; Colevas AD; Licitra L; Harrington KJ; Kasper S; Vokes EE; Even C; Worden F; Saba NF; Docampo LCI; Haddad R; Rordorf T; Kiyota N; Tahara M; Lynch M; Jayaprakash V; Li L; Gillison ML
    Oral Oncol; 2018 Jun; 81():45-51. PubMed ID: 29884413
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nivolumab in Squamous Cell Carcinomas of the Head and Neck (SCCHN): A Real-world Outcome Study in Ontario, Canada.
    Zereshkian A; Shafi R; Pond GR; Hotte SJ
    J Immunother; 2024 May; 47(4):123-127. PubMed ID: 38230590
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The Evolving and Future Role of Taxanes in Squamous Cell Carcinomas of the Head and Neck: A Review.
    Mody MD; Gill HS; Saba NF
    JAMA Otolaryngol Head Neck Surg; 2016 Sep; 142(9):898-905. PubMed ID: 27389786
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Protein methyltransferases and demethylases dictate CD8+ T-cell exclusion in squamous cell carcinoma of the head and neck.
    Vougiouklakis T; Bao R; Nakamura Y; Saloura V
    Oncotarget; 2017 Dec; 8(68):112797-112808. PubMed ID: 29348866
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rational Combinations of Targeted Therapy and Immune Checkpoint Inhibitors in Head and Neck Cancers.
    Chai AWY; Yee PS; Cheong SC
    Front Oncol; 2022; 12():837835. PubMed ID: 35372020
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DNA-based immunotherapy for HPV-associated head and neck cancer.
    Aggarwal C
    Immunotherapy; 2016 Oct; 8(10):1187-92. PubMed ID: 27605067
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
    Przybylski K; Majchrzak E; Weselik L; Golusiński W
    Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pooled analysis of nivolumab treatment in patients with recurrent/metastatic squamous cell carcinoma of the head and neck in the United States and Germany.
    Singh P; McDonald L; Waldenberger D; Welslau M; von der Heyde E; Gauler T; Dietz A
    Head Neck; 2021 Nov; 43(11):3540-3551. PubMed ID: 34487397
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Current Standard of Care in Squamous Cell Carcinoma of the Head and Neck (SCCHN) - Prevention, diagnostics, prognostication and therapy].
    Pogorzelski M; Grünwald V
    Dtsch Med Wochenschr; 2019 Dec; 144(24):1691-1696. PubMed ID: 31791073
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cost-effectiveness analysis of nivolumab compared to pembrolizumab in the treatment of recurrent or metastatic squamous cell carcinoma of the head and neck.
    Yeh J; Guddati AK
    Am J Cancer Res; 2020; 10(6):1821-1826. PubMed ID: 32642293
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.